Table 2.
The impact of statin use on dementia incidence.a
| Dementia and subtypes | No. of events/total number | 10-Year cumulative incidence (%) | SHR (95% CI)b |
|
|---|---|---|---|---|
| Unadjusted | Adjusted | |||
| All types of dementia | 10,031 | |||
| Statin non-use | 5757/50,291 | 11.0 | Ref. | Ref. |
| Statin use | 4274/54,004 | 7.3 | 0.73 (0.70–0.76) | 0.80 (0.76–0.84) |
| Alzheimer's disease | 2250 | |||
| Statin non-use | 1374/50,291 | 2.6 | Ref. | Ref. |
| Statin use | 876/54,004 | 1.5 | 0.64 (0.58–0.69) | 0.72 (0.63–0.82) |
| Vascular dementia | 1831 | |||
| Statin non-use | 954/50,291 | 1.8 | Ref. | Ref. |
| Statin use | 877/54,004 | 1.5 | 0.91 (0.83–1.00) | 0.82 (0.70–0.95) |
| Unspecified dementia | 5950 | |||
| Statin non-use | 3429/50,291 | 6.4 | Ref. | Ref. |
| Statin use | 2521/54,004 | 4.3 | 0.73 (0.69–0.77) | 0.80 (0.75–0.85) |
Abbreviations: Ref., reference; SHR, sub-distribution hazards ratio; CI, confidence interval.
a
Inverse probability of treatment weighting (IPTW) was used to balance the covariates between statin users and non-users. A multivariable-adjusted model further accounted for the demographic covariates, comorbidities, and medications.
b
We calculated the sub-distribution hazards ratio (SHR) and 95% confidence interval (95% CI) using the Fine Gray's test for equality of the cumulative functions between each exposure group after accounting for competing risks of all-cause mortality.